Capricor Therapeutics (CAPR) Earns Media Sentiment Score of 0.25

Media headlines about Capricor Therapeutics (NASDAQ:CAPR) have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Capricor Therapeutics earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.8820618806928 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Capricor Therapeutics traded up $0.05, hitting $1.43, during midday trading on Wednesday, Marketbeat reports. The company’s stock had a trading volume of 1,531,500 shares, compared to its average volume of 372,257. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25. The stock has a market capitalization of $38.42 million, a price-to-earnings ratio of -3.25 and a beta of -3.22.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Capricor Therapeutics had a negative return on equity of 485.43% and a net margin of 110.98%. The business had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.63 million. equities analysts forecast that Capricor Therapeutics will post -0.48 EPS for the current year.

Several brokerages have weighed in on CAPR. ValuEngine upgraded shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Zacks Investment Research cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 30th. Maxim Group began coverage on shares of Capricor Therapeutics in a research note on Wednesday, May 16th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Capricor Therapeutics in a research note on Friday, May 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $4.91.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Insider Buying and Selling by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply